Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists
作者:Tomoaki Hasui、Norio Ohyabu、Taiichi Ohra、Koji Fuji、Takahiro Sugimoto、Jun Fujimoto、Kouhei Asano、Masato Oosawa、Sachiko Shiotani、Nobuhiro Nishigaki、Keiji Kusumoto、Hideki Matsui、Atsushi Mizukami、Noriyuki Habuka、Satoshi Sogabe、Satoshi Endo、Midori Ono、Christopher S. Siedem、Tony P. Tang、Cassandra Gauthier、Lisa A. De Meese、Steven A. Boyd、Shoji Fukumoto
DOI:10.1016/j.bmc.2014.07.038
日期:2014.10
In the course of our study on selective nonsteroidal mineralocorticoid receptor (MR) antagonists, a series of novel benzoxazine derivatives possessing an azole ring as the core scaffold was designed for the purpose of attenuating the partial agonistic activity of the previously reported dihydropyrrol-2-one derivatives. Screening of alternative azole rings identified 1,3-dimethyl pyrazole 6a as a lead compound with reduced partial agonistic activity. Subsequent replacement of the 1-methyl group of the pyrazole ring with larger lipophilic side chains or polar side chains targeting Arg817 and Gln776 increased MR binding activity while maintaining the agonistic response at the lower level. Among these compounds, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (37a) showed highly potent in vitro activity, high selectivity versus other steroid hormone receptors, and good pharmacokinetic profiles. Oral administration of 37a in deoxycorticosterone acetate-salt hypertensive rats showed a significant blood pressure-lowering effect with no signs of antiandrogenic effects. (C) 2014 Elsevier Ltd. All rights reserved.